Intensity Therapeutics Q1 net loss $2.4M; cash $10.2M; resumes trial enrollment

INTENSITY THERAPEUTICS, INC.

2026-Q1 EPS reported -$0.96

Net loss $2.4M for Q1 2026 vs $3.3M in Q1 2025; R&D expenses fell to $1.2M from $2.2M.
Cash and equivalents $10.2M at March 31, 2026; $60M ATM facility established in March 2026.
Phase 2 INVINCIBLE-4 TNBC study: 71.4% pCR in INT230-6+SOC arm vs 33% in SOC alone; 44% fewer grade 3+ AEs.
Swissmedic approved resumption of INVINCIBLE-4 enrollment; plan to resume Q2 2026 and start France sites.
Decision to resume limited U.S. enrollment in Phase 3 INVINCIBLE-3 soft tissue sarcoma study by Q3 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INTENSITY THERAPEUTICS, INC. reported the three months ended March 31, 2026 results: net income net loss was $2.4 million.

Period: the three months ended March 31, 2026
Net income: net loss was $2.4 million
Result: reported results

Exact text from the filing

31, 2025. This increase was partially offset by lower stock-based compensation and one-time expenses related to our reverse stock split in February 2026. Overall, net loss was $2.4 million for the three months ended March 31, 2026, compared to a net loss of $3.3 million for the three months ended March 31, 2025. As of March 31, 2026, cash and cash equivalents

View on SEC.gov

Browse all earnings releases →

INTENSITY THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001567264-26-000047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.